0
0
Industry
Geography
Report Type
Themes
Price
Publication date
Published Date
  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Blueprint Medicines Corp

    Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is precision therapy company that inventing medicines for people with cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. It also offer GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Homology Medicines Inc

    Homology Medicines Inc (Homology) is a genetic medicines company that discovers and develops gene therapies to treat genetic disorders. The company is investigating pipeline programs HMI-102, a gene therapy for the treatment of phenylketonuria (PKU); and HMI-202, an investigational gene therapy targeting metachromatic leukodystrophy. It is also evaluating HMI-103, an investigational gene editing program for the treatment of pediatric phenylketonuria, and HMI-203, an investigational gene therapy for the treatment of Hunter syndrome. Homology gene-editing technology is used in DNA repairs,...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Revolution Medicines Inc

    Revolution Medicines Inc (Revolution Medicines) is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Editas Medicine Inc

    Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, BlueRock Therapeutics,...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Huadong Medicine Co Ltd

    Huadong Medicine Co Ltd (Huadong Medicine) is a producer and supplier of pharmaceutical products. The company’s product range includes capsules to treat nephropathy, respiratory and immune system diseases; and granules. It offers immunosuppressive and gastrointestinal agents, endocrine, digestive system, antineoplastic, cardiovascular, and antibiotic drugs. The company also manufactures cosmetology and medical equipment. It also involves in handling research and development across various areas including diabetes, oncology, autoimmune field, and others. Huadong Medicine is headquartered in Hangzhou, Zhejiang, China.

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Zhejiang Medicine Co Ltd

    Zhejiang Medicine Co Ltd (Zhejiang Medicine) develops, manufactures, and commercializes biological drugs, pharmaceutical intermediates, and bio-pesticides. The company's product portfolio consists of animal nutrition, active pharmaceutical ingredients (APls) and intermediates; antibiotics and human nutrition products including vitamin E, natural vitamin E, vitamin A, vitamin D3 and other pharmaceutical preparations. The company provides its products in large and small volume injections, freeze dried powder injections, tablets, hard and soft capsules, pills and oral solutions. It has two research and development centers,...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Praxis Precision Medicines Inc

    Praxis Precision Medicines Inc (Praxis) is a clinical-stage biopharmaceutical company that translates genetic insights for the development of novel therapies to treat central nervous system disorders. The company’s pipeline program includes PRAX-114, PRAX-944, PRAXIS-050 and PRAXIS-040 which are molecule GABA receptors for the treatment of psychiatry and movement disorders. Praxis provides programs such as PRAX-562, PRAX-222, PRAX-020, SCN2A-LCF, SYNGAP1, PCDH19, and PRAXIS-030 are used for the treatment of genetic epilepsies. Praxis is headquartered in Cambridge, Massachusetts, the US.

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Jiangsu Hengrui Medicine Co Ltd

    Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its...

  • Product Insights

    New
    $500 | March 2024
    Product Insights
    New

    Net Present Value Model: Everest Medicines Ltd’s SPR-206

    Empower your strategies with our Net Present Value Model: Everest Medicines Ltd's SPR-206 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

  • Product Insights

    New
    $500 | March 2024
    Product Insights
    New

    Net Present Value Model: Disc Medicine Inc’s DISC-0974

    Empower your strategies with our Net Present Value Model: Disc Medicine Inc's DISC-0974 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.